Last updated on June 2019

A Controlled Trial of Erenumab in Migraine Prevention


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Migraine
  • Age: Between 20 - 65 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures.
  • Japanese subjects greater than or equal to 20 to less than or equal to 65 years of age upon entry into screening.
  • History of migraine (with or without aura) for greater than or equal to 12 months before screening according to the International Headache Society Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2018) based on medical records and/or patient self-report
  • Migraine frequency: Chronic Migraine (CM) or Episodic Migraine (EM) over the 3 months before screening (refer to Section 5.6 for definition of migraine day) based on the following criteria:
    1. CM is defined as greater than or equal to 15 headache days per month of which greater than or equal to 8 headache days on average across the 3 months meet criteria as migraine days
    2. EM is defined as less than 15 headache days per month of which at least 4 or more headache days on average across the 3 months meet criteria as migraine days

Exclusion Criteria:

  • Subjects greater than 50 years of age at migraine onset.
  • History of cluster headache or hemiplegic migraine headache.
  • Unable to differentiate migraine from other headaches.
  • Migraine with continuous pain, in which the subject does not experience any pain-free periods (of any duration) during the 1 month before the screening period.
  • Malignancy, except non-melanoma skin cancers, cervical or breast ductal carcinoma in situ within the last 5 years.

Other exclusion criteria may apply

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.